Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Joshua Gustine, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Marcela Maus, Matthew J. Frigault, Noopur Raje

Blood (2024) 144 (Supplement 1): 79.

https://doi.org/10.1182/blood-2024-212135

Published: 2024

Journal Articles

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Blood (2024) 144 (Supplement 1): 7126.

https://doi.org/10.1182/blood-2024-194895

Published: 2024

Journal Articles

Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

Elizabeth K. O'Donnell, Clifton C. Mo, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil C. Munshi, Shonali Midha, Diana Cirstea, Paul G. Richardson, Noopur Raje, Andrew J. Yee

Blood (2024) 144 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2024-201768

Published: 2024

Journal Articles

Hypogammaglobulinemia and Daratumumab in Multiple Myeloma: Risk Factors, Infections, Immunoglobulin Replacement, and Mortality

Joseph S Hong, Jr., Baijun Zhou, Andrew J. Yee, Sara Barmettler

Blood (2024) 144 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2024-193205

Published: 2024

Journal Articles

First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2024-199174

Published: 2024

Journal Articles

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Andrew J. Yee, Paul G. Richardson, Sikander Ailawadhi, Saurabh Chhabra, Eli Muchtar, Jesús G. Berdeja, Shambavi Richard, Jeffrey V Matous, Urvi A. Shah, Mark A. Schroeder, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Sagar Lonial

Blood (2024) 144 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2024-204255

Published: 2024

Journal Articles

Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

Joanna Blocka, Seong Gu Heo, Shonali Midha, Nathaniel G. Tadros, Steffen B. Kulp, Julia Frede, Marius Mathies, Nikhil C. Munshi, Andrew J. Yee, Jens G. Lohr

Blood (2024) 144 (Supplement 1): 1898.

https://doi.org/10.1182/blood-2024-198713

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

Farah Rexha, Joshua Gustine, Ryan Han, Rie Nakamoto-Matsubara, Cristina Panaroni, Rajib Shome, Valentina Nardi, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, Noopur Raje

Blood (2024) 144 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2024-211622

Published: 2024

Journal Articles

An ATLAS to map MRD with peripheral blood

Andrew J. Yee

Blood (2024) 144 (9): 919–920.

https://doi.org/10.1182/blood.2024025189

Published: 2024

Journal Articles

Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide

Diana Cirstea, Rajib Shome, Joseph James Connolly, Emilie Duvallet, Amanda N. R. Joyce, Victor Moyo, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje

Blood (2023) 142 (Supplement 1): 2017.

https://doi.org/10.1182/blood-2023-189332

Published: 2023

Journal Articles

Evaluating Physician-AI Interaction for Multiple Myeloma Management: Paving the Path Towards Precision Oncology

Barbara D Lam, Zeshan Hussain, Fernando A Acosta-Perez, Irbaz Bin Riaz, Maia Jacobs, Andrew J. Yee, David Sontag

Blood (2023) 142 (Supplement 1): 2281.

https://doi.org/10.1182/blood-2023-182421

Published: 2023

Journal Articles

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob Laubach, Jacalyn Rosenblatt, Nora Horick, Paul G. Richardson, Noopur Raje, Diana Cirstea

Blood (2023) 142 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2023-181019

Published: 2023

Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2023-174550

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Narsis Attar, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Matthew J. Frigault, Noopur Raje

Blood (2023) 142 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2023-182212

Published: 2023

Journal Articles

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Charlotte E. Graham, Won-Ho Lee, Hadley R. Wiggin, Valentina M. Supper, Mark B. Leick, Filippo Birocchi, Andrew J. Yee, Angelina Petrichenko, John Everett, Frederic D. Bushman, Hossein Sadrzadeh, Otto Rapalino, Daniel Chiu, Isabel Arrillaga-Romany, Marcela V. Maus, Matthew J. Frigault, Kathleen M. E. Gallagher

Blood (2023) 142 (14): 1248–1252.

https://doi.org/10.1182/blood.2023021429

Published: 2023

Includes: Supplemental data

Journal Articles

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Philipp Karschnia, Kevin C. Miller, Andrew J. Yee, Kai Rejeski, P. Connor Johnson, Noopur Raje, Matthew J. Frigault, Jorg Dietrich

Blood (2023) 142 (14): 1243–1248.

https://doi.org/10.1182/blood.2023020571

Published: 2023

Journal Articles

Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy

Johannes M. Waldschmidt, Sankalp Arora, Tushara Vijaykumar, Noori Sotudeh, Praveen Anand, Hannah Stuart, Julia Frede, Tim Campbell, Shari M. Kaiser, Manisha Lamba, Nikhil C Munshi, Kenneth C. Anderson, Andrew J. Yee, Birgit Knoechel, Jens G. Lohr, Noopur Raje

Blood (2022) 140 (Supplement 1): 9925–9926.

https://doi.org/10.1182/blood-2022-168734

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje

Blood (2022) 140 (Supplement 1): 7282–7283.

https://doi.org/10.1182/blood-2022-156328

Published: 2022

NARROW

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

Hypogammaglobulinemia and Daratumumab in Multiple Myeloma: Risk Factors, Infections, Immunoglobulin Replacement, and Mortality

First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

An ATLAS to map MRD with peripheral blood

Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide

Evaluating Physician-AI Interaction for Multiple Myeloma Management: Paving the Path Towards Precision Oncology

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only